ABSI Absci Corporation Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
02:10
Aug 31
Aug 31
New hair-loss drugs could reward investors.
Investors are focused on a new crop of hair-loss treatment companies after GLP-1 success showed consumers will pay for appearance-related drugs. Cosmo has a topical lotion that could reach market by early next year; Verodmix has a pill and just went public; Absi is developing a twice-yearly shot seen as the most differentiated. No new FDA-approved treatments have arrived since the late 1990s, and cash-pay customers are already spending heavily on hair restoration.
MED
18:33
Aug 23
Aug 23
Author lists 40 tickers across sectors to watch on Monday.
Author lists 40 tickers across sectors to watch on Monday, expecting some to rally and others to pull back, but frames it as monitoring rather than taking positions.
LOW
14:27
Aug 23
Aug 23
Author highlights five biotech stocks as top picks following an AI-driven breakthrough.
Author highlights five biotech stocks as top picks following an AI-driven breakthrough in biotech, but frames them as names to watch with theses coming soon, not explicit positions.
LOW
14:46
Aug 21
Aug 21
Author confirms closing their ABSI position
Author confirms they are no longer in ABSI, having publicly closed the trade to reallocate capital to other ideas.
MED
23:56
Aug 19
Aug 19
Author takes profits on ABSI position.
Author discloses taking profits on ABSI position to rotate capital into a higher conviction trade.
MED
00:16
Jun 30
Jun 30
Author sold their ABSI position after hitting a target but notes it may go higher and that.
Author sold their ABSI position after hitting a target but notes it may go higher and that another trader added it to their portfolio today.
LOW
10:59
Jun 18
Jun 18
States a short-term trade for Absi and longer holds for Abcl and IOVA.
States a short-term trade for Absi and longer holds for Abcl and IOVA, but provides no catalyst or directional reasoning.
LOW
10:44
Jun 18
Jun 18
Buy ABSI as a play on AI-augmented biotech/digital biology convergence.
Buy ABSI as a play on AI-augmented biotech/digital biology convergence; author frames this as a high-regret-risk omission for portfolios lacking exposure to the trend.
MED
15:42
Jun 04
Jun 04
Author identifies ABSI as a proteonomics/AI antibody stock moving in the biotech sector.
Author identifies ABSI as a proteonomics/AI antibody stock moving in the biotech sector, no directional view.
LOW
14:55
Jun 04
Jun 04
Author evaluates three biotech tickers as potential long-term holds depending on clinical data.
Author evaluates three biotech tickers as potential long-term holds depending on clinical data, explicitly ruling out ABSI, but offers no personal position or forward call.
LOW
14:50
Jun 04
Jun 04
Author reiterates a prior bullish biotech thesis from research discord but provides no current.
Author reiterates a prior bullish biotech thesis from research discord but provides no current position disclosure or forward directional call in the tweet itself.
10:29
Jun 02
Jun 02
The author corrects a parent claim by noting AMD has capital deals with biotech firms.
The author corrects a parent claim by noting AMD has capital deals with biotech firms for proteonomics, citing ABSI as one example without taking a directional position.
LOW
00:56
Jun 02
Jun 02
Author explicitly says ABSI, ABCL, and IOVA are their bets on the digital biology narrative.
Author explicitly says ABSI, ABCL, and IOVA are their bets on the digital biology narrative, which they expects to run hard.
MED
18:12
May 29
May 29
Author discloses a current long position in ABSI alongside ABCL as a bet on AI-driven.
Author discloses a current long position in ABSI alongside ABCL as a bet on AI-driven personalized medicine and digital biology becoming a major sector within five years.
MED
16:18
May 06
May 06
Holding spot ABSI after taking 268% profit on calls.
Holding spot ABSI after taking 268% profit on calls; sees it running to ~$9 on insider open-market buying.
HIGH
17:53
May 04
May 04
Holds ABSI calls up 200% — bullish, 'there's always a bull market somewhere'.
MED
14:56
May 04
May 04
AI biotech designs zero-prior epitope monoclonal antibodies
Discloses an existing long position in ABSI, highlighting its capability to design monoclonal antibodies against zero-prior epitopes.
MED
01:51
May 01
May 01
Holds ABSI calls up 185% in 2 weeks; conviction from insider buys by ex-Philips CEO.
Holds ABSI calls up 185% in 2 weeks; conviction from insider buys by ex-Philips CEO and ex-AstraZeneca EVP.
HIGH
15:32
Apr 27
Apr 27
Holds ABSI calls bought at $3.15, now up 105% — 'there's always a bull market somewhere'.
MED
10:22
Apr 19
Apr 19
Likes Absci; accommodating FDA + AI-augmented biotech R&D thesis, accumulate equity pullbacks.
MED
17:38
Apr 17
Apr 17
Names Absci as a current pick (AI-biotech / FDA thesis restated from prior posts).
LOW
03:20
Apr 17
Apr 17
Bull case for Absci: AI proliferating oncology/therapeutics.
Bull case for Absci: AI proliferating oncology/therapeutics; highlights ABSI funded through 2028 as de-risking the long.
MED
About ABSI Analyst Coverage
Buzzberg tracks ABSI (Absci Corporation Common Stock) across 3 sources. 11 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (50%). 22 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Avalon Purnell, __con_, CryptoCondom.